The HOPE4MCI study: A randomized double‐blind assessment of AGB101 for the treatment of MCI due to AD

The HOPE4MCI study: A randomized double‐blind assessment of AGB101 for the treatment of MCI due to AD

Abstract INTRODUCTION In addition to the accumulation of amyloid plaques and neurofibrillary tangles, the presence of excess neural activity is a pathological hallmark of Alzheimer's disease (AD) and a prognostic indicator for progression of AD pathology and clinical/cognitive worsening in mild...

Full description

Bibliographic Details
Main Authors: Richard Mohs, Arnold Bakker, Sharon Rosenzweig‐Lipson, Michael Rosenblum, Russell L. Barton, Marilyn S. Albert, Sharon Cohen, Scott Zeger, Michela Gallagher
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
AGB101
Alzheimer's disease
clinical trial
hippocampus
levetiracetam
mild cognitive impairment
Online Access:https://doi.org/10.1002/trc2.12446

Internet

https://doi.org/10.1002/trc2.12446

Similar Items